Form 4: Travere Therapeutics Director Roy D. Baynes Reports Acquisition of Shares and Stock Options

Roy D. Baynes, a director of Travere Therapeutics, reported the acquisition of 6,500 shares of common stock and 19,500 stock options on May 15, 2025, according to a Form 4 filing with the SEC.

Summary

• On May 15, 2025, Roy D. Baynes, a director of Travere Therapeutics, Inc., reported transactions involving the company's securities.
• Baynes acquired 6,500 shares of common stock at a price of $0, resulting from an automatic equity grant under the Issuer's 2018 Equity Incentive Plan.
• Following the transaction, Baynes directly owns 37,500 shares of common stock.
• Baynes also acquired 19,500 stock options with an exercise price of $21.15, exercisable from May 15, 2026, and expiring on May 15, 2035.
• These options also came at a price of $0.
• Following the transaction, Baynes directly owns 19,500 stock options.
• The equity award vests over a one-year period.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard regulatory filing detailing stock transactions by a director. The acquisition of shares and options could be interpreted as a positive sign of confidence, but it's not definitively bullish.

Positives

• The acquisition of shares and stock options by a director could be seen as a positive sign, indicating confidence in the company's future prospects.

Industry Context

Form 4 filings are standard disclosures required by the SEC to provide transparency into the transactions of company insiders. These filings are closely watched by investors to gauge the sentiment of company leadership and their confidence in the company's performance.

Comparison to Industry Standards

• Director compensation packages often include stock options and equity grants to align their interests with those of shareholders.
• The vesting period of one year for the equity award is a common practice in the industry.
• The exercise price of $21.15 for the stock options would need to be compared to the current market price of Travere Therapeutics' stock to assess the potential value of the options.

Stakeholder Impact

• The reported transactions may influence investor sentiment regarding Travere Therapeutics.
• The increased ownership stake of a director could signal confidence in the company's future performance.

Key Dates

Keywords

Form 4, Travere Therapeutics, Director, Roy D. Baynes, Stock Options, Equity Grant, Beneficial Ownership, Securities